{
  "documentMetadata": {
    "title": "Prosthetic Joint Infection",
    "lastUpdated": "2025-07-21",
    "sourceFile": "Prosthetic Joint Infection.pdf"
  },
  "content": [
    {
      "type": "header",
      "level": 1,
      "text": "Clinical Setting"
    },
    {
      "type": "list",
      "items": [
        "Suspect infected joint if sinus tract or wound drainage; acutely painful prosthesis; chronically painful prosthesis; or high ESR or CRP in association with a painful prosthesis."
      ]
    },
    {
      "type": "list",
      "items": [
        "Treat based on culture and sensitivity results"
      ]
    },
    {
      "type": "list",
      "items": [
        "Empiric therapy is not recommended prior to obtaining cultures results."
      ]
    },
    {
      "type": "list",
      "items": [
        "Withholding therapy for 2 weeks in medically stable patients appropriate and improves recovery of organisms in culture."
      ]
    },
    {
      "type": "list",
      "items": [
        "Three surgical options:",
        "Intraoperative inspection, debridement, exchange of polyethylene liner (if present) and hardware retention.",
        "Appropriate if duration of symptoms < 3 weeks or implantation < 30 days; otherwise removal of prosthesis recommended if possible.",
        "1 stage, direct exchange strategy",
        "2 stage: sequential debridement and prosthesis removal then later re-implantation"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Diagnosis"
    },
    {
      "type": "list",
      "items": [
        "Criteria for diagnosis of hip or knee periprosthetic joint infection: New Engl J Med. 2023;388: 251"
      ]
    },
    {
      "type": "header",
      "level": 2,
      "text": "Diagnosis of infection :"
    },
    {
      "type": "list",
      "items": [
        "Synovial fluid WBCs >3000cells/mmÂ³ or >95% PMNs.",
        "Radiographs may show periprosthetic radiolucency (>2 mm), rapidly progressive osteolysis, or periosteal reaction, but can be normal in early infection.",
        "CT and MRI can better define bone changes, soft tissue abscesses, and sinus tracts, though metal artifact can be a limitation.",
        "When other imaging is inconclusive, labeled leukocyte scintigraphy or FDG-PET/CT can help identify sites of inflammation and infection.",
        "Synovial culture yield increased by injecting fluid into blood culture bottles",
        "Cultures should be held, especially in infections of the shoulder, for 10 days with blind subculture to maximize recovery of Cutibacterium (formerly Propionibacterium) acnes (J Clin Microbiol 54:3043, 2016)."
      ]
    },
    {
      "type": "diagnosticTest",
      "diagnosticTestData": {
        "name": "Synovasure",
        "analyte": "alpha-defensin",
        "sampleType": "synovial fluid",
        "sensitivity": 0.85,
        "specificity": 0.925,
        "notes": "Rapid lateral flow immunoassay that can detect a-defensin in synovial fluid in about 10 minutes. Useful in the diagnosis of PJI (Bone Joint J. 2018; 100-B:703-711; Bone Joint J. 2018 Jan;100-B:66-72)"
      }
    },
    {
      "type": "diagnosticTest",
      "diagnosticTestData": {
        "name": "Multiplex PCR",
        "sampleType": "Synovial fluid",
        "notes": "Can detect common joint pathogens (alive or dead). Note: PCR may allow pathogen detection in the presence of antibiotic therapy. Advantages: Results available within few hrs. Disadvantages: Multiplex PCR platforms do not help colonization vs infection due to coagulase-negative staphylococci. Need positive culture for in vitro susceptibility testing"
      }
    },
    {
      "type": "list",
      "items": [
        "Culture yield may be further increased by sonication (if available) of removed prosthesis (N Engl J Med 357:654, 2007)."
      ]
    },
    {
      "type": "list",
      "items": [
        "Role of Next Generation Sequencing (Clin Infect Dis 2023;76:359)"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Etiologies"
    },
    {
      "type": "list",
      "items": [
        "Staphylococcus epidermidis (MSSE or MRSE), other coagulase-negative staphylococci",
        "Staphylococcus aureus (MSSA or MRSA)",
        "Streptococci",
        "Enterococci",
        "Cutibacterium (Propionibacterium) acnes; Cutibacterium (Propionibacterium) avidum; Propionibacterium granulosum (Clin Infect Dis 2018;66:54)",
        "Gram-negative enteric bacilli",
        "Pseudomonas aeruginosa"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Primary Regimens"
    },
    {
      "type": "header",
      "level": 2,
      "text": "Debridement and prosthesis retention strategy:"
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "appliesTo": {
          "description": "MSSA/MSSE"
        },
        "components": [
          {
            "drug": "Nafcillin",
            "dose": "2 gm",
            "route": "IV",
            "frequency": "q4h"
          },
          {
            "drug": "Oxacillin",
            "dose": "2 gm",
            "route": "IV",
            "frequency": "q4h",
            "connector": "or"
          },
          {
            "drug": "Rifampin",
            "dose": "300 mg",
            "route": "po",
            "frequency": "bid",
            "connector": "+"
          }
        ],
        "durationDetail": {
          "fixedDuration": "2-6 weeks"
        }
      }
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "appliesTo": {
          "description": "MSSA/MSSE"
        },
        "components": [
          {
            "drug": "Cefazolin",
            "dose": "2 gm",
            "route": "IV",
            "frequency": "q8h"
          },
          {
            "drug": "Rifampin",
            "dose": "300 mg",
            "route": "po",
            "frequency": "bid",
            "connector": "+"
          }
        ],
        "durationDetail": {
          "fixedDuration": "2-6 weeks"
        }
      }
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "appliesTo": {
          "description": "MSSA/MSSE"
        },
        "components": [
          {
            "drug": "Ciprofloxacin",
            "dose": "750 mg",
            "route": "po",
            "frequency": "bid"
          },
          {
            "drug": "Levofloxacin",
            "dose": "750 mg",
            "route": "po",
            "frequency": "q24h",
            "connector": "or"
          },
          {
            "drug": "Rifampin",
            "dose": "300 mg",
            "route": "po",
            "frequency": "bid",
            "connector": "+"
          }
        ],
        "durationDetail": {
          "fixedDuration": "3-6 months"
        },
        "notes": "3 months may be adequate for total hip arthroplasty. Confirm that isolate is susceptible to fluoroquinolones and rifampin in vitro (see Comments). In retrospective study, unplanned drug discontinuation occurred in 35.6% of patients treated with a fluoroquinolone vs 3% of patient's treated with non-fluoroquinolone drug (Clin Infect Dis 2021;73:850 & 857-editorial)"
      }
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "appliesTo": {
          "description": "MRSA/MRSE"
        },
        "components": [
          {
            "drug": "Vancomycin",
            "dose": "15-20 mg/kg",
            "route": "IV",
            "frequency": "q8-12h"
          },
          {
            "drug": "Rifampin",
            "dose": "300 mg",
            "route": "po",
            "frequency": "bid",
            "connector": "+"
          }
        ],
        "durationDetail": {
          "fixedDuration": "2-6 weeks"
        }
      }
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "appliesTo": {
          "description": "MRSA/MRSE"
        },
        "components": [
          {
            "drug": "Ciprofloxacin",
            "dose": "750 mg",
            "route": "po",
            "frequency": "bid"
          },
          {
            "drug": "Levofloxacin",
            "dose": "750 mg",
            "route": "po",
            "frequency": "q24h",
            "connector": "or"
          },
          {
            "drug": "Rifampin",
            "dose": "300 mg",
            "route": "po",
            "frequency": "bid",
            "connector": "+"
          }
        ],
        "durationDetail": {
          "fixedDuration": "3-6 months"
        },
        "notes": "3 months may be adequate for total hip arthroplasty. Confirm that isolate is susceptible to fluoroquinolones and rifampin in vitro (see Comments)."
      }
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "appliesTo": {
          "description": "Streptococci (Groups A, B, C, D, viridans, other)"
        },
        "components": [
          {
            "drug": "Penicillin G",
            "dose": "20 million units",
            "route": "IV",
            "frequency": "continuous infusion q24h or in 6 divided doses"
          },
          {
            "drug": "Ceftriaxone",
            "dose": "2 gm",
            "route": "IV",
            "frequency": "q24h",
            "connector": "or"
          }
        ],
        "durationDetail": {
          "fixedDuration": "4-6 weeks"
        },
        "notes": "NOTE: Poorer outcomes with retention compared with removal and exchange, (Clin Infect Dis 2017 Jun 15;64(12):1742)"
      }
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "appliesTo": {
          "description": "Enterococcus spp. (see comments)"
        },
        "condition": "Pen-susceptible",
        "components": [
          {
            "drug": "Ampicillin",
            "dose": "200 mg/kg/day",
            "route": "IV",
            "frequency": "in divided doses q6h"
          },
          {
            "drug": "Penicillin G",
            "dose": "20 million units/day",
            "route": "IV",
            "frequency": "continuous infusion or in 6 divided doses",
            "connector": "or"
          }
        ],
        "durationDetail": {
          "fixedDuration": "4-6 weeks"
        }
      }
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "appliesTo": {
          "description": "Enterococcus spp. (see comments)"
        },
        "condition": "Pen-resistant",
        "components": [
          {
            "drug": "Vancomycin",
            "dose": "15 mg/kg",
            "route": "IV",
            "frequency": "q12h"
          }
        ],
        "durationDetail": {
          "fixedDuration": "4-6 weeks"
        }
      }
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "appliesTo": {
          "description": "Cutibacterium (Propionibacterium) acnes"
        },
        "components": [
          {
            "drug": "Penicillin G",
            "dose": "20 million units",
            "route": "IV",
            "frequency": "continuous infusion or in 6 divided doses"
          },
          {
            "drug": "Ceftriaxone",
            "dose": "2 gm",
            "route": "IV",
            "frequency": "q24h",
            "connector": "or"
          }
        ],
        "durationDetail": {
          "fixedDuration": "4-6 weeks"
        }
      }
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "appliesTo": {
          "description": "Gram-negative enteric bacilli"
        },
        "components": [
          {
            "drug": "Ertapenem",
            "dose": "1 gm",
            "route": "IV",
            "frequency": "q24h"
          },
          {
            "drug": "other beta-lactam (e.g., Ceftriaxone 2 gm IV q24h OR Cefepime 2 gm IV q12h, based on susceptibility)",
            "connector": "or"
          }
        ],
        "durationDetail": {
          "fixedDuration": "4-6 weeks"
        }
      }
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "appliesTo": {
          "description": "P. aeruginosa (see Comments)"
        },
        "components": [
          {
            "drug": "Cefepime",
            "dose": "2 gm",
            "route": "IV",
            "frequency": "q12h"
          },
          {
            "drug": "Meropenem",
            "dose": "1 gm",
            "route": "IV",
            "frequency": "q8h",
            "connector": "or"
          },
          {
            "drug": "Tobramycin",
            "dose": "5.1 mg/kg",
            "route": "IV",
            "frequency": "once daily",
            "connector": "+"
          }
        ],
        "durationDetail": {
          "fixedDuration": "4-6 weeks"
        }
      }
    },
    {
      "type": "header",
      "level": 2,
      "text": "1-stage exchange strategy"
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "appliesTo": {
          "description": "MSSA/MSSE or MRSA/MRSE"
        },
        "durationDetail": {
          "fixedDuration": "3 months"
        },
        "notes": "IV/po regimen as above"
      }
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "appliesTo": {
          "description": "Other listed etiologies"
        },
        "durationDetail": {
          "fixedDuration": "4-6 weeks"
        },
        "notes": "Regimen as above"
      }
    },
    {
      "type": "header",
      "level": 2,
      "text": "2-stage exchange strategy"
    },
    {
      "type": "paragraph",
      "text": "Check pre-reimplantation ESR and CRP to assess success of treatment. Some aspirate joint space for culture prior to re-implantation. This may be problematic if antibiotic-loaded cement spacer is present."
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "appliesTo": {
          "description": "MSSA/MSSE or MRSA/MRSE"
        },
        "durationDetail": {
          "fixedDuration": "6 weeks"
        },
        "notes": "IV/po regimen for 6 weeks post-explantation of infected device (IDSA guidelines do not routinely recommend Rifampin as a companion drug with Vancomycin or a parenteral beta-lactam if all hardware and foreign material are removed, although it's often used for MRSA or MRSE infections and should be used with Ciprofloxacin or Levofloxacin)"
      }
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "appliesTo": {
          "description": "Other listed etiologies"
        },
        "durationDetail": {
          "fixedDuration": "4-6 weeks"
        },
        "notes": "Regimen as above"
      }
    },
    {
      "type": "header",
      "level": 1,
      "text": "Alternative Regimens"
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "appliesTo": {
          "description": "MSSA/MSSE or MRSA/MRSE"
        },
        "components": [
          {
            "drug": "Daptomycin",
            "dose": "6-8 mg/kg",
            "route": "IV",
            "frequency": "q24h"
          },
          {
            "drug": "Linezolid",
            "dose": "600 mg",
            "route": "po/IV",
            "frequency": "bid",
            "connector": "or"
          },
          {
            "drug": "Rifampin",
            "dose": "300 mg",
            "route": "po",
            "frequency": "bid",
            "connector": "+"
          }
        ]
      }
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "appliesTo": {
          "description": "Streptococci (Groups A, B, C, D, viridans, other)"
        },
        "components": [
          {
            "drug": "Vancomycin",
            "dose": "15 mg/kg",
            "route": "IV",
            "frequency": "q12h"
          }
        ]
      }
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "appliesTo": {
          "description": "Enterococcus spp."
        },
        "components": [
          {
            "drug": "Daptomycin",
            "dose": "6-8 mg/kg",
            "route": "IV",
            "frequency": "q24h"
          },
          {
            "drug": "Linezolid",
            "dose": "600 mg",
            "route": "po/IV",
            "frequency": "bid",
            "connector": "or"
          }
        ]
      }
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "appliesTo": {
          "description": "Cutibacterium (Propionibacterium) acnes"
        },
        "components": [
          {
            "drug": "Vancomycin",
            "dose": "15 mg/kg",
            "route": "IV",
            "frequency": "q12h"
          },
          {
            "drug": "Clindamycin",
            "dose": "300-450 mg",
            "route": "po",
            "frequency": "qid",
            "connector": "or"
          }
        ]
      }
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "appliesTo": {
          "description": "Gram-negative enteric bacilli"
        },
        "components": [
          {
            "drug": "Ciprofloxacin",
            "dose": "750 mg",
            "route": "po",
            "frequency": "bid"
          }
        ]
      }
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "appliesTo": {
          "description": "P. aeruginosa"
        },
        "components": [
          {
            "drug": "Ciprofloxacin",
            "dose": "750 mg",
            "route": "po",
            "frequency": "bid"
          },
          {
            "drug": "Ciprofloxacin",
            "dose": "400 mg",
            "route": "IV",
            "frequency": "q8h",
            "connector": "or"
          }
        ]
      }
    },
    {
      "type": "header",
      "level": 1,
      "text": "Antimicrobial Stewardship"
    },
    {
      "type": "list",
      "items": [
        "Rifampin is bactericidal vs. surface-adhering, slow-growing, and biofilm-producing bacteria.",
        "Never use Rifampin alone due to rapid development of resistance.",
        "Randomized trial of Rifampin + Fusidic acid terminated due to significant drug-drug interaction that reduced target Fusidic acid plasma concentrations by about half (Clin Infect Dis 63:1599, 2016).",
        "For fluoroquinolone-resistant isolate consider using another highly bioavailable agent to which the isolate is susceptible, e.g., TMP-SMX, Doxycycline, Minocycline, Amoxicillin-Clavulanate, Clindamycin, or Linezolid.",
        "Watch for toxicity (e.g., marrow suppression, neuropathy) if Linezolid is used for more than 2 weeks of therapy.",
        "Addition of antibacterials to temporary cement joint spacers; available data do not allow judgement as to efficacy or lack of efficacy: Clin Infect Dis 55:1474, 2012."
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Comments"
    },
    {
      "type": "list",
      "items": [
        "Excellent review: New Engl J Med. 2023;388: 251",
        "Enterococcal infection: addition of aminoglycoside optional.",
        "P. aeruginosa infection: consider adding aminoglycoside if isolate is susceptible, although whether this improves cure rates is not clear.",
        "Prosthesis retention most important risk factor for treatment failure (Clin Microbiol Infect 16:1789, 2010).",
        "(Linezolid 600 mg bid + Rifampin 300 mg bid) may be effective as salvage therapy in cases when device removal is not possible (Antimicrob Agents Chemother 55:4308, 2011); watch for linezolid toxicity!",
        "Success rate for retained prosthetic joint infected with Staph. aureus 55% in recent study which included some chronic infections (Clin Infect Dis 56:182, 2013).",
        "If prosthesis is retained in chronic infection, consider long-term, suppressive antimicrobial therapy, particularly for staphylococcal infections: depending on in vitro susceptibility options include TMP-SMX, Doxycycline, Minocycline, Amoxicillin, Ciprofloxacin, Cephalexin. In a retrospective cohort study of 136 pts with a median age of 83, the 2 year survival without an adverse event or death was 61%: Eur J Clin Microbiol Infect Dis 2017. doi.org/10.1007/s10096-017-2971-2)",
        "Culture yield may be further increased by sonication (if available) of removed prosthesis (N Engl J Med 357:654, 2007).",
        "IDSA treatment guidelines, Clin Infect Dis 56:e1, 2013."
      ]
    }
  ]
}
